Psoriasis Area Severity Index (PASI)

Clinical Overview & History

The Psoriasis Area and Severity Index (PASI) is the gold standard clinical scoring system developed in 1978 by Fredriksson and Pettersson. It was designed to provide a quantitative, reproducible measure of the severity and extent of plaque psoriasis. PASI is extensively used in dermatology clinical trials to evaluate the efficacy of therapeutic agents (such as biological drugs, systemic therapies, and phototherapy) and in clinical practice to guide treatment escalation and monitor disease progression over time.

Standardizing psoriasis severity with the PASI score helps clinicians establish baseline severity, set therapeutic targets, and objectively document treatment success.

Pathophysiology and Scoring Criteria

Psoriasis is a chronic, immune-mediated inflammatory skin condition characterized by hyperproliferation of keratinocytes and inflammatory cell infiltration, leading to the formation of well-demarcated, scaly plaques. The clinical severity of these plaques is characterized by three key morphologic changes:

1. Erythema (E): Redness, reflecting increased vascularity and active inflammation.
2. Induration/Thickness (I): Plaque elevation, reflecting epidermal hyperplasia and dermal edema.
3. Desquamation/Scaling (D): The presence of silvery-white scales, reflecting abnormal keratinocyte desquamation.

For the PASI calculation, the human body is divided into four anatomical regions, each with a different assigned weight reflecting its proportion of the total body surface area (BSA):

• Head (H): 10% of BSA (weight $= 0.1$)
• Trunk (T): 30% of BSA (weight $= 0.3$)
• Upper Limbs (U): 20% of BSA (weight $= 0.2$)
• Lower Limbs (L): 40% of BSA (weight $= 0.4$)

Within each region, the percentage of skin affected is graded on an area scale from 0 to 6:

• 0: 0% involvement
• 1: $1% - 9%$ involvement
• 2: $10% - 29%$ involvement
• 3: $30% - 49%$ involvement
• 4: $50% - 69%$ involvement
• 5: $70% - 89%$ involvement
• 6: $90% - 100%$ involvement

Additionally, the average severity of Erythema, Induration, and Desquamation in each region is graded from 0 (none) to 4 (maximum severity). In our calculator, the user inputs the sum of these three severity scores (each 0 to 4, for a total of 0 to 12) for each region.

Formula & Scoring Interpretation

The total PASI score is calculated using the following formula:

Where $A$ is the area score (0-6) and the terms $(E + I + D)$ represent the sum of severity parameters (0-12) for each region (Head, Trunk, Upper limbs, and Lower limbs). The maximum possible score is 72. Clinical interpretation grades severity as follows:

• PASI < 10 (Mild Psoriasis): Typically managed with topical therapies (corticosteroids, vitamin D analogs), localized phototherapy, and emollients.
• PASI ge 10 (Moderate-to-Severe Psoriasis): Often warrants systemic treatments (methotrexate, cyclosporine, acitretin), phototherapy, or biologic agents (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors) as topical agents alone are rarely sufficient.

Step-by-Step Clinical Scenario

Consider a clinical case: A 35-year-old female patient with plaque psoriasis is evaluated in a dermatology clinic.

• Head: Approximately 5% of the scalp is involved (Area Score = 1). The average plaque features are: Erythema = 2, Induration = 1, Scaling = 2 (Severity Sum = 5).
• Trunk: 45% of the trunk is involved (Area Score = 3). Plaque features: Erythema = 3, Induration = 2, Scaling = 2 (Severity Sum = 7).
• Upper Limbs: No plaques are present (Area Score = 0, Severity Sum = 0).
• Lower Limbs: 15% of the legs are involved (Area Score = 2). Plaque features: Erythema = 3, Induration = 3, Scaling = 3 (Severity Sum = 9).

Let's calculate the PASI score:

• Head component: $0.1 \times 5 \times 1 = 0.5$
• Trunk component: $0.3 \times 7 \times 3 = 6.3$
• Upper Limbs component: $0.2 \times 0 \times 0 = 0.0$
• Lower Limbs component: $0.4 \times 9 \times 2 = 7.2$

$\text{PASI Total} = 0.5 + 6.3 + 0.0 + 7.2 = 14.0\text{ points}$

A PASI score of 14.0 indicates moderate-to-severe plaque psoriasis, which makes her a candidate for systemic or biological therapies.

Clinical Utility and Limitations

PASI is the gold standard for clinical research and is vital for tracking clinical response markers like PASI 75 (a 75% reduction in PASI from baseline), PASI 90, or PASI 100 (complete clearance).

However, it has significant limitations in routine clinical practice: it is time-consuming, has high inter-observer variability, and does not capture the severe psychosocial impact of the disease. Consequently, clinicians often measure the patient's quality of life separately using the Dermatology Life Quality Index (DLQI) alongside the PASI.

⚠️ Medical Disclaimer: This calculator is for educational and reference purposes only. It is not intended to diagnose, treat, or cure any disease, and should not be used as a substitute for professional clinical judgment.